“Drug companies aren’t contributing hundreds of millions of dollars [to copay charities] for altruistic reasons”
Because we self-insure and CVS Caremark is just the PBM, this could all be adjusted back to the way it used to be with a few keystrokes.
Can you talk to HR and see if they can get your generics reclassified during the next insurance year? I think you could make a strong case for their own plan changes are driving you to the extremely high priced non generics and if they moved the generics into another category everyone will save a huge amount of money?
I can try but I don't think it will go anywhere. I work for a Fortune 50 company that has decimated their HR department. We no longer have an HR representative for our department, we now have to send an email to a generic mailbox and hope that we get some sort of reply. I used to know someone who was in the area of plan design and communication, I'll have to see if she is still employed or has been shown the door like most of the department.Quote from: iolaire on May 24, 2016, 05:31:43 AMCan you talk to HR and see if they can get your generics reclassified during the next insurance year? I think you could make a strong case for their own plan changes are driving you to the extremely high priced non generics and if they moved the generics into another category everyone will save a huge amount of money?
I worked for a company of 40,000 employees that self insured. We were offered standard policies from several vendors that were indistinguishable from non-self insured policies from the same vendors. The difference is my employer was billed the sum total of all employee claims plus an administrative fee.
The Trans-Pacific Partnership would provide large pharmaceutical firms new rights and powers to increase medicine prices and limit consumers' access to cheaper generic drugs. This would include extensions of monopoly drug patents that would allow drug companies to raise prices for more medicines and even allow monopoly rights over surgical procedures. For people in developing countries involved in the TPP, these rules could be deadly – denying consumers access to HIV/AIDS, tuberculosis and cancer drugs.The TPP would also establish new rules that could undermine government efforts to contain rising medicine prices in developed countries like the United States. An analysis of the final TPP text shows taxpayer-funded public health programs would be exposed to pharmaceutical company attacks and constrain future policy reforms to reduce prescription drug costs for Americans. The text explicitly binds Medicare to TPP rules that would limit proposed policy changes to tamp down healthcare costs for seniors.
Proposed intellectual property rules in the TPP would limit competition from generic drug manufacturers that reduce drug prices and improve access to treatment, and would accelerate already soaring medicine and vaccine prices.
The literature suggests that in-center hemo patient has about a 1/300 chance of contracting Hep-C. Fresenius now has a policy of paying for one of the new Hep-C drug regimens for in-center acquired Hep-C.
How does that infection start? Is it contamination of the blood? Or something you touch/breath? Those odds don't seem so good..